[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eosinophilic-esophagitis-eoe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eosinophilic-esophagitis-eoe":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,72,93,124,148,170,193,218,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638367","natural-history-of-eosinophilic-esophagitis-in-adult-and-pediatric-population-100638367",false,"NCT07614633","Natural History of Eosinophilic Esophagitis in Adult and Pediatric Population","Natural History of Eosinophilic Esophagitis in Adult and Pediatric Population: a Multicentric Prospective Study in Italy","Inclusion Criteria:\n\n* patients with an established diagnosis of Eosinophilic esophagitis;\n* aged ≥5 years;\n* who gave written informed consent.\n\nExclusion Criteria:\n\n* under 5 years old;\n* Patients who are illiterate;\n* Patients who are unwilling to participate","ALL","5 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Eosinophilic esophagitis (EoE) is a Th2-mediated disease induced by ingestion of ambiental and alimentary allergens. Incidence of EoE is increasing in recent years. Young male subjects are more often affected by EoE. Esophageal eosinophilic infiltrate causes different symptoms of esophageal dysfunction (i.e. dysphagia, food impaction, chest pain, heartburn). In pediatric population symptoms are nonspecific (failure to thrive, vomiting) and more common to be misdiagnosed.\n\nSymptoms are commonly sporadic and underestimated by the patients. Therefore, specialistic evaluations are often delayed during the following months and years. Moreover, esophageal symptoms are often not investigated or associated with other diseases especially in pediatric population (i.e. gastroesophageal reflux disease). For this reason, diagnosis of EoE is often delayed. It is known from literature that diagnostic delay in EoE causes prolonged inflammation of the esophagus that may lead to esophageal fibrosis and stenosis with worsening of symptoms. Proton pump inhibitors (PPIs) and topical steroids are the first line medicines to induce EoE remission. Prolonged clinical remission is described in 60% of adult patients with PPIs. Recently orodispersible budesonide showed clinical remission after 1 year nearby in 90% of adult patients. Orodispersible budesonide is effective also in chidren with an efficacy in maintaining remission at lowest effective dosage after 60 weeks in around 78% of patients. Dysphagia Symptom Questionnaire (DSQ) is a validated tool used in order to measure clinical activity (dysphagia) in adult and pediatric patients with EoE. Italian version of the DSQ is not available in literature. Little is known in literature about the natural history of EoE patients, in particular about sustained clinical remission and appearance of complications (i.e. food impaction) during a prolonged follow-up period. Aim of our two-phase prospective study is to evaluate the clinical and endoscopic response at the current available therapies and the appearance of complications during a prolonged follow-up period in a cohort of adult and pediatric population.",[24],"Eosinophilic Esophagitis (EoE)",[26,24,27],"NATURAL HISTORY","Dysphagia Symptom Questionnaire","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2025-09-01",{"date":36,"type":20},"2027-12",{"name":38,"class":39},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100601583","phase-3-a-study-of-dupilumab-in-small-children-with-an-allergic-condition-of-the-esophagus-food-pipe-eosinophilic-esophagitis-100601583","NCT07112378","A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis","A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to \u003C15 kg With Active Eosinophilic Esophagitis","Key Inclusion Criteria:\n\n1. Pediatric patients aged ≥6 months and weighing ≥5 kg and \\\u003C15 kg at screening with active EoE\n2. History of symptom(s) determined by the investigator to be the result of EoE in the month prior to screening, as defined in the protocol\n3. Baseline endoscopic biopsies, performed during the screening period, with a demonstration on central reading of intraepithelial eosinophilic infiltration in at least 2 of the 3 biopsied esophageal regions, as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Prior participation in a dupilumab clinical trial or past or current treatment with dupilumab\n2. Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening. Patients on a food-elimination diet must remain on the same diet throughout the study\n3. Other causes of esophageal eosinophilia or the following conditions: eosinophilic gastroenteritis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)\n4. Active Helicobacter pylori infection\n5. History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery\n6. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening\n7. History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopic procedure\n8. Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline standard of care endoscopy\n\nNOTE: Other Protocol-Defined Inclusion\u002FExclusion Criteria Apply","6 Months","6 Years",{"count":51,"type":20},20,"INTERVENTIONAL",[54],"PHASE3","This study is researching an experimental drug called dupilumab (called \"study drug\"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.\n\nThe aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)",[24],[58,59,60],"Type 2 Inflammatory","Allergic\u002Fimmune-mediated","Esophageal dysfunction","2026-06-17",{"date":63,"type":32},"2026-06-18",{"date":65,"type":32},"2025-11-10",{"date":67,"type":20},"2028-10-09",{"name":69,"class":70},"Regeneron Pharmaceuticals","INDUSTRY",11,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100569383","a-us-registry-of-eosinophilic-esophagitis-pediatric-adolescent-and-adult-patients-treated-with-dupixent-as-standard-of-care-100569383","NCT06693531","A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care","A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care","EDESIA","Key Inclusion Criteria:\n\n1. Initiating treatment with DUPIXENT® for EoE according to the USPI\n2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \\\u003C12 years must be able to understand and complete registry-related questionnaires\n\nKey Exclusion Criteria:\n\n1. Patients who have a contraindication to DUPIXENT® according to the USPI\n2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment\n3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)\n\nNOTE: Other protocol defined inclusion\u002Fexclusion criteria apply","1 Year",{"count":82,"type":20},350,"3 Years","This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).\n\nThe purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.\n\nPossible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.\n\nPatient questionnaires will measure the following:\n\n* How EoE makes one feel\n* EoE signs and\u002For symptoms, eg, how difficult it is to swallow\n* How EoE affects quality-of-life\n* How EoE impacts aspects of daily life\n* How EoE symptoms have changed throughout the study",[24],{"date":63,"type":32},{"date":88,"type":32},"2024-11-22",{"date":90,"type":20},"2030-05-22",{"name":69,"class":70},55,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":52,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100639754","phase-2-a-trial-of-upadacitinib-for-non-responsive-eosinophilic-esophagitis-100639754","NCT07588568","A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis","A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)","ATUNE","Inclusion Criteria:\n\n1. Age 18-65 years.\n2. Diagnosis of EoE per 2018 AGREE consensus guidelines.\n3. Currently using topical corticosteroids (TCS) for EoE treatment (either swallowed budesonide, ≥2mg total daily dose or swallowed fluticasone, ≥1760 mcg total daily dose) for at least 8 weeks (prior to the screening endoscopy) and willing to remain on the same TCS treatment with no changes to regimen throughout the study.\n4. Have active esophageal eosinophilia (peak eosinophil count ≥15 eos\u002Fhpf \\[eosinophils per high power field\\]) as measured during the screening endoscopy despite ongoing therapy with TCS.\n5. Have active symptoms of esophageal dysfunction attributed to EoE (such as trouble swallowing, heartburn, reflux, vomiting, chest pain, painful swallowing, abdominal pain, malnutrition, etc.) in the 4 weeks prior to the screening endoscopy.\n6. Willing to continue all current EoE treatments (including medications such as proton pump inhibitors (PPIs), diet elimination, etc.) throughout participation in the study.\n7. Able to read, comprehend, and sign consent form.\n8. Ability to take oral medication (swallow a pill) and be willing to adhere to the study regimen (follow dosing instructions and complete study procedures).\n\nExclusion Criteria:\n\n1. Use of systemic corticosteroids (such as prednisone or methylprednisolone) within 4 weeks of the screening endoscopy.\n2. Use of dupilumab (dupixent) within 3 months of the screening endoscopy.\n3. Use of estrogen (including estrogen-containing contraceptives and other hormonal treatments) within 30 days of screening.\n4. Previous esophageal resection.\n5. Medical instability making it unsafe to perform an upper endoscopy.\n6. At the Screening \u002F Baseline or Enrollment Visit, meeting any of the following conditions:\n\n   6.1. Two or more prior episodes of herpes zoster (shingles), or one or more episodes of disseminated herpes zoster;\n\n   6.2. One or more prior episodes of disseminated herpes simplex (including eczema herpeticum);\n\n   6.3. Human immunodeficiency virus (HIV) infection, defined as confirmed positive anti-HIV antibody (HIV Ab) test or a positive HIV Ab\u002FAg test;\n\n   6.4. Active tuberculosis (TB) or latent TB, or meet TB exclusionary parameters;\n\n   6.5. Active infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days, or oral\u002Fintramuscular anti-infectives within 14 days prior to the visit;\n\n   6.6. Active diverticulitis within the past 3 months;\n\n   6.7. Chronic recurring infection and\u002For active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study;\n\n   6.8. COVID-19 infection: In participants who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the visit of asymptomatic participants. Participants with mild\u002Fmoderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics (fever reducers such as ibuprofen, aspirin, and paracetamol) for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Participants may be rescreened if deemed appropriate by the investigator based upon the participant's health status.\n\n   6.9. Hepatitis B (HBV) and Hepatitis C (HCV) screening values that meet the following criteria at the most recent testing prior to the first dose of study drug:\n\n   6.9.1. HBV: hepatitis B surface antigen (HBs Ag) positive (+) test or detectable HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for participants who are hepatitis B core antibody (HBc Ab) positive (+);\n\n   6.9.2. HCV: detectable HCV ribonucleic acid (RNA) in any participant with anti-HCV antibody (HCV Ab).\n7. At the Screening \u002F Baseline or Enrollment visit, any of the following medical diseases or disorders:\n\n   7.1. Prior history of\n   * cerebrovascular accident (stroke),\n   * myocardial infarction (heart attack),\n   * coronary stenting,\n   * coronary bypass surgery (heart bypass surgery),\n   * or thrombotic events including deep venous thrombosis (DVT) and pulmonary embolism (PE);\n\n   7.2. History of an organ transplant which requires continued immunosuppression;\n\n   7.3. History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and\u002For other products in the same class;\n\n   7.4. History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;\n\n   7.5. Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; participants with a history of gastric banding\u002Fsegmentation (such as Lap Band or Realize Band) are not excluded;\n\n   7.6. History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;\n\n   7.7. Current uncontrolled hypertension defined as a confirmed systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;\n\n   7.8. Known inherited or acquired conditions that predispose to hypercoagulability;\n\n   7.9. Current or past smokers;\n\n   7.10. In patients 50 years of age and older:\n   * High-density lipoprotein (HDL) cholesterol level of \\\u003C40mg per deciliter,\n   * Diabetes mellitus,\n   * Family history of premature coronary heart disease,\n   * Extraarticular rheumatoid arthritis.\n\n   7.11. Severe hepatic impairment (i.e., Child Pugh C cirrhosis).\n8. Participants of child-bearing potential who do not meet the following:\n\n   8.1. Participants must not have a positive serum pregnancy test (blood test) at the Screening Visit and must have a negative urine pregnancy test at the Enrollment visit prior to the first dose of study drug.\n\n   8.2. Participants with an abnormal or inconclusive serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes and a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.\n\n   8.3. Participants with a urine pregnancy test at the Enrollment visit that is borderline or ambiguous must have a serum pregnancy test performed. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n\n   8.4. Participants of childbearing potential who are not able and\u002For willing to practice at least 1 protocol-specified method of birth control that is highly effective throughout participation in the study (from Screening through at least 30 days after the last dose of study drug. Use of estrogen-containing contraception is not allowable. Participants of non-childbearing potential do not need to use birth control.\n9. Participants who are pregnant, breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug.\n10. Participants who received treatment with any investigational drug of chemical or biologic nature within 30 days or five half-lives (whichever is longer) prior to the screening endoscopy or who are currently enrolled in another interventional clinical study.\n11. Participants with systemic use of known strong cytochrome P450 3A (CYP3A) inhibitors or strong CYP3A inducers within 30 days or five half-lives (whichever is longer) of the screening endoscopy through the end of study participation: Herbal therapies and other traditional medicines with unknown effect on CYP3A taken systemically are prohibited within 30 days prior to the screening endoscopy and throughout the study. Herbal therapies and other traditional medicines are defined as any herbal formulation intended to treat or prevent health problems and may include supplements based on which herbs the participant is taking.\n12. Participants who have received any live vaccine with replicating potential within 30 days prior to the first dose of study drug or have expected need of vaccination with any live vaccine with replicating potential during study participation including at least 30 days after the last dose of study drug. Live vaccines that are incapable of replicating are permitted.\n13. Screening laboratory values that meet the following criteria at the most recent testing prior to the first dose of study drug:\n\n    13.1. Serum aspartate transaminase (AST) \\> 2 × upper limit of normal (ULN); 13.2. Serum alanine transaminase (ALT) \\> 2 × ULN; 13.3. Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \\\u003C 30 mL\u002Fmin\u002F1.73 m2; 13.4. Total white blood cell (WBC) count \\\u003C 2,500\u002FµL; 13.5. Absolute neutrophil count (ANC) \\\u003C 1,200\u002FµL; 13.6. Platelet count \\\u003C 100,000\u002FµL; 13.7. Absolute lymphocyte count \\\u003C 750\u002FµL; 13.8. Hemoglobin \\\u003C 9 g\u002FdL.\n14. Known allergic reaction, significant sensitivity, or intolerance to Janus kinase (JAK) inhibitors or their components\n15. History of or current clinically significant medical or psychiatric conditions or any other reason that in the opinion of the Investigator would interfere with the participant's participation in this study, would place the participant at risk by participating in the study or would make the participant an unsuitable candidate to receive study drug.\n16. Inability to read or understand English.","18 Years","65 Years",{"count":104,"type":20},52,[106],"PHASE2","The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).\n\nThe main question it aims to answer are:\n\n\\- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?\n\nParticipants will:\n\n* Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib\n* Fill out surveys and answer health questions\n* Visit the clinic every 4 weeks for checkups and tests",[109,110,24],"EoE","Eosinophilic Esophagitis",[110,109,112,113],"upadacitinib","rinvoq","NOT_YET_RECRUITING","2026-05-06",{"date":117,"type":32},"2026-05-15",{"date":119,"type":20},"2026-07",{"date":121,"type":20},"2030-06",{"name":123,"class":39},"University of North Carolina, Chapel Hill",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":52,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100610995","trial-of-partial-enteral-nutrition-with-dairy-free-diet-in-eosinophilic-esophagitis-100610995","NCT07234825","Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis","Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis Induction of Remission","Inclusion Criteria:\n\n* Pediatric patients 1 year to 21 of age presenting with chronic symptoms of dysphagia, odynophagia, vomiting or heartburn, chronic abdominal pain, weight loss, picky eating, to outpatient gastroenterology clinic and are planning to undergo EGD for evaluation.\n\nExclusion Criteria:\n\n* Non-English-Speaking Subjects, adults unable to consent, wards of the state, pregnant women, and prisoners will be excluded from the study.\n* Patients with autoimmune conditions such as inflammatory bowel disease. Patients with prior esophageal or intestinal surgeries.\n* Patients with history of eating disorders or ARFID.\n* Patients with fistulizing or fibrotic disease on baseline EGD.\n* Patients who have received proton pump inhibitory therapy in the past month.","21 Years",{"count":133,"type":20},36,[135],"NA","This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.",[24],"2026-04-13",{"date":140,"type":32},"2026-04-16",{"date":142,"type":32},"2026-03-18",{"date":144,"type":20},"2028-12-31",{"name":146,"class":70},"Kate Farms Inc",1,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":147},"100604964","surface-emg-testing-on-swallowing-in-eoe-patients-100604964","NCT07156357","Surface EMG Testing on Swallowing in EoE Patients","sEMG Assessment of Swallowing and Bolus Preparation","sEMG","Inclusion Criteria:\n\n* Controls\n\n  * Normal video swallow or score of 0 for dysphagia on ESSAI questionnaire\n  * absence of dysphagia\n  * age \\>18 EoE participants\n  * Documentation of EoE diagnosis by histologic criteria,\n  * \\>15 eos\u002Fhpf on most recent esophageal biopsy\n  * age \\>18\n\nExclusion Criteria:\n\n* Abnormal baseline video swallow\n* lack of MSK coordination to eat test meal\n* underlying neuromuscular disorder.",true,{"count":158,"type":20},30,"Evaluating swallowing food with surface electromyography (EMG) machine in patients with Eosinophilic Esophagitis",[24],"2025-09-04",{"date":163,"type":32},"2025-09-05",{"date":165,"type":32},"2025-08-04",{"date":167,"type":20},"2027-06",{"name":169,"class":39},"Mayo Clinic",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":52,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100597399","trans-cervical-and-trans-abdominal-ultrasound-for-monitoring-esophageal-thickness-in-eosinophilic-esophagitis-100597399","NCT07057986","Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis","Inclusion Criteria:\n\n* Age ≥18 years.\n* Suspected or confirmed diagnosis of EoE based on clinical symptoms (e.g., dysphagia, food impaction).\n* Scheduled for upper endoscopy with biopsies.\n* Able and willing to consent to participation.\n\nExclusion Criteria:\n\n* Prior esophageal surgery or anatomical abnormalities.\n* Presence of other gastrointestinal disorders affecting the esophagus (e.g., esophageal cancer, achalasia, Barrett's esophagus).\n* Pregnancy.\n* Inability to undergo US due to anatomical or physical limitations.",{"count":177,"type":20},100,[135],"Eosinophilic Esophagitis (EoE) is a chronic inflammatory disease characterized by eosinophilic infiltration of the esophageal mucosa, leading to symptoms of dysphagia and food impaction. Currently, upper endoscopy with biopsy is the gold standard for diagnosis and disease monitoring, but it is invasive, costly, and associated with procedural risks. The investigators want to use ultrasound imaging as a non-invasive assessment of esophageal wall thickness as a surrogate marker for mucosal inflammation.\n\nParticipants will undergo ultrasound assessment at the same day of endoscopy, and than after 3-6 months (optional). The correlation between US-measured esophageal thickness and histological eosinophil counts will be measured.",[24],[182],"eosinophilic esophagitis","2025-07-24",{"date":185,"type":32},"2025-07-29",{"date":187,"type":20},"2025-08-01",{"date":189,"type":20},"2028-08-01",{"name":191,"class":192},"Sheba Medical Center","OTHER_GOV",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":156,"sex":16,"minAge":101,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":147},"100593937","local-clinical-and-immunological-responses-in-eosinophilic-esophagitis-eoe-patients-role-of-mucosal-barrier-function-and-type-ii-inflammation-100593937","NCT07012928","Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation","SINFONIA","Inclusion Criteria:\n\nEoE patient group with dupilumab or topical budesonide Previous diagnosis of active EoE confirmed by histopathology e.g. presence of 15 or more eosinophilic granulocytes per hpf in mid or proximal esophageal biopsies Scheduled to start with dupilumab or topical budesonide as regular care 18 to 75 years of age Written informed consent must be obtained and documented\n\nEoE patient group with active EoE Previous diagnosis of active EoE confirmed by histopathology e.g. presence of 15 or more eosinophilic granulocytes per hpf in mid or proximal esophageal biopsies Scheduled for an upper endoscopy 18 to 75 years of age Written informed consent must be obtained and documented\n\nNon-EoE control group Scheduled for a upper endoscopy for other, non-esophageal related, symptoms 18 to 75 years of age Written informed consent must be obtained and documented\n\nExclusion Criteria:\n\nEoE patient group with dupilumab, topical budesonide and with active EoE Use of oral or systemic antihistaminics, oral cromoglicates, systemic corticosteroids, leukotriene inhibitors or monoclonal antibodies, in the month preceding the study Proven gastroesophageal reflux disease or other cause for esophageal eosinophilia, History of peptic ulcer disease, History of Barrett's esophagus, History of gastro intestinal cancer or ASA class III, IV or V\n\nNon-EoE control group Symptoms suggestive of esophageal disease or other disease that may infolve the esophagus Personal history of atopic, skin or systemic diseases","75 Years",{"count":202,"type":20},56,"Eosinophilic esophagitis (EoE) is an allergic inflammation of the esophagus. If not treated properly, inflammation and narrowing of the esophagus can occur. This can eventually lead to food impaction. Food allergens play an important role in the pathogenesis of EoE, as demonstrated by endoscopic and clinical resolution of EoE once the causative food is removed from the diet and exacerbation when the same food is reintroduced Similarly, amino acid-based\n\nelemental diets are effective in both adults and children with EoE. However, the exact mechanism by which food allergens can initiate inflammation in EoE is still unknown, as there are limited data on the early local esophageal immune response after challenge with a specific food trigger. Previous research has shown that this can be treated with antacids (PPI) and corticosteroids. This reduces the permeability of the esophagus (which is increased in EoE), but not to the level of healthy individuals. Most likely this is due to a mild underlying allergic inflammation that persists under treatment with the above agents. The idea is that dupilumab inhibits this type II inflammation, which will further reduce the permeability. In addition, the effect of food allergens on esophageal biopsies from both EoE patients and healthy patients will be examined. This will then be compared to the biopsies taken after the use of dupilumab.",[24],[110,206,207,208],"Dupilumab","Permeability esophagus","TEER","2025-06-05",{"date":211,"type":32},"2025-06-10",{"date":213,"type":20},"2025-07",{"date":215,"type":20},"2028-05-31",{"name":217,"class":39},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":147},"100546058","esophageal-string-test-monitoring-to-monitor-eosinophilic-esophagitis-during-oral-immunotherapy-100546058","NCT06389994","Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy","Monitoring Eosinophilic Esophagitis During Food Oral Immunotherapy Using Esophageal String Test","Inclusion Criteria:\n\nAn individual must meet all of the following criteria:\n\n* Male or female, aged 7 to 18 years old, inclusive\n* Have a history of Immunoglobulin (IgE)-mediated food allergy\n* Considering using oral immunotherapy (OIT) for food allergies at CHOP°\n* Able \\& willing to swallow the esophageal capsule\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n* Willing to comply with all study procedures and be available for the duration of the study.\n\nExclusion Criteria:\n\n* Known or expected need for MRI imaging during the study period\n* Known connective tissue disease\n* Known eosinophilic disorder including any eosinophilic gastrointestinal disorder and hypereosinophilic disorder\n* Past history of caustic ingestion or other esophageal injury\n* History of esophageal surgery or dilation (i.e.: tracheoesophageal fistula repair)\n* History of gastrointestinal motility disorder including esophageal achalasia\n* History of inflammatory bowel disease\n* Unwilling or unable to swallow the EST\n* Oral or intravenous steroids in the preceding 60 days (not including swallowed topical fluticasone, budesonide, etc.)\n* Participation in a clinical study that may interfere with participation in this study\n* Pregnant or lactating females\n* Limited English proficiency\n* Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.","7 Years","17 Years",{"count":228,"type":20},75,"Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits.",[24],"2025-05-23",{"date":233,"type":32},"2025-05-29",{"date":235,"type":32},"2024-04-01",{"date":237,"type":20},"2026-10-01",{"name":239,"class":39},"Children's Hospital of Philadelphia",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":52,"phases":249,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":147},"100567267","phase-4-effect-of-dupilumab-on-the-muscle-function-of-the-esophagus-food-pipe-in-participants-with-eosinophilic-esophagitis-eoe-100567267","NCT06665971","Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)","Effect of Dupilumab on Esophageal Peristaltic Function in Participants with Eosinophilic Esophagitis","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study including regular follow-up with the study monitor.\n* Persons aged 22-75 years of age, males and females, of all ethnic races.\n* Participants must be diagnosed with PPI resistant eosinophilic esophagitis (EoE) (proven by endoscopic biopsy showing \\> 15 eosinophils\u002FHPF prior to and 8 weeks after treatment with PPI) will be eligible to participate in the study.\n* Ability to take subcutaneous medication and willing to adhere to the 12-week Dupilumab regimen.\n* Eligible participants must not have taken inhalational, oral or IV steroids for at least 8 weeks prior to the study.\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if they have any of the followings:\n\n* Prior participation in a Dupilumab clinical trial, or past or current treatment with Dupilumab\n* Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening. Participants on a food-elimination diet must remain on the same diet throughout the study.\n* Other causes of esophageal eosinophilia for the following conditions: hyper eosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), Participants with eosinophilic gastroenteritis are eligible, provided they meet other eligibility criteria.\n* Active Helicobacter pylori infection, history of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery\n* Participant with significant other medical condition that would prevent treatment with Dupilumab and close follow up of their EOE condition.\n* Initiation, discontinuation, or change in the dosage regimen of the following medications within 8 weeks prior to the baseline endoscopy:\n* Proton pump inhibitors (except for participants who require a PPI trial prior to baseline endoscopy)\n* Leukotriene inhibitors\n* Nasal and\u002For inhaled corticosteroids\n* Participants on a stable dose of these medications for at least 8 weeks prior to the baseline endoscopy may be included in the study but must not change the dose during the study.\n* Participants who have asthma and use an asthma medicine c) have atopic dermatitis, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, or prurigo nodularis and also have asthma, then do not change or stop their corticosteroid medicine or other asthma medicine without talking to the investigators. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.\n* Initiation, discontinuation, or change in the dosage regimen of SC immunotherapy (SCIT), participants on a stable dose of these medications for at least 1 year prior to visit 1 may be included in the study but must not change the dose during the study.\n* Treatment with sublingual immunotherapy (SLIT)\n* Treatment with oral immunotherapy (OIT) within 6 months prior to visit 1.\n* The following treatments within 3 months prior to screening, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the study:\n* Systemic immunosuppressant\u002Fimmunomodulating drugs, including but not limited to systemic corticosteroids, omalizumab, cyclosporine, mycophenolate-mofetil, interferon-gamma \\[IFN-γ\\], Janus kinase inhibitors, azathioprine, and methotrexate: One-time use of a corticosteroid as a part of the anesthetic preparation used during each endoscopy procedure is allowed.\n* Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to visit.\n* Planned or anticipated use of any prohibited medications and procedures during the study\n* Planned or anticipated major surgical procedure during the study.\n* Treatment with a live (attenuated) vaccine within 4 weeks prior to the baseline visit\n* Active parasitic infection or suspected parasitic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before randomization.\n* Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before baseline visit. Note: A participant may be re-screened after the infection resolves.\n* Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (e.g., tuberculosis \\[TB\\], non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator.\n* Tuberculosis testing will be performed if required by regulatory authorities or ethics committees (ECs).\n* Known history of human immunodeficiency virus (HIV) infection\n* Established diagnosis of hepatitis B viral infection at the time of screening or positive for hepatitis B surface antigen (HBsAg) at the time of screening. Participants who have gained immunity for hepatitis B virus infection after vaccination (participants who are HBsAg negative, hepatitis B surface antibody \\[HBsAb\\] positive, and hepatitis B core antibody \\[HBcAb\\] negative are eligible for the study). Participants with positive HBcAb are eligible for the study only if hepatitis B virus DNA level is undetectable.\n* Established diagnosis of hepatitis C viral (HCV) infection at the time of screening. Participants positive for hepatitis C Ab are eligible for the study only if HCV RNA is negative.\n* On current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis, or hepatic failure, or has evidence of liver disease as indicated by persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases (alanine aminotransferase \\[ALT\\] and\u002For aspartate aminotransferase \\[AST\\]) more than 3 times the upper limit of normal \\[ULN\\] during the screening period)\n* Any of the following abnormal lab values at screening:\n\n  * Platelets \\\u003C100 ×103\u002FμL\n  * Neutrophils \\\u003C1.5 × 103\u002FμL\n  * Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2 If an abnormal value is detected at screening, a repeat test should be performed to confirm the abnormality. Only if the repeat test confirms the abnormality would the participant be categorized as a screen failure. eGFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation in adult participants and using the Bedside Schwartz formula in participants \\\u003C18 years of age.\n* If the participant: are taking oral, topical, or inhaled corticosteroid medicines, have asthma and use an asthma medicine, have atopic dermatitis, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, or prurigo nodularis and also have asthma\n* Do not change or stop corticosteroid medicine or other asthma medicine without talking to the investigators. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back. \"\n* Severe concomitant illness (es) that, in the investigator's judgment, would adversely affect the participant's participation in the study. Examples include but are not limited to short life expectancy, uncontrolled diabetes, cardiovascular conditions (e.g., NYHA Class III or IV cardiac failure), severe renal conditions (e.g., severe nephrotic syndrome), hepatobiliary conditions (e.g., Child-Pugh class B or C), neurological conditions (e.g., demyelinating diseases), active major autoimmune diseases (e.g., lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other severe endocrinologic, gastrointestinal, metabolic, pulmonary, or lymphatic diseases. The specific justification for participants excluded under this criterion will be noted in study documents (chart notes, case report forms \\[CRF\\].\n* History of malignancy within 5 years prior to screening, except completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin.\n* History of alcohol or drug abuse within 6 months prior to screening\n* Any other medical or psychological condition including relevant laboratory abnormalities at screening that, in the opinion of the investigator, suggest a new and\u002For insufficiently understood disease, may present an unreasonable risk to the study participant as a result of his\u002Fher participation in this clinical trial, may make participant's participation unreliable, or may interfere with study assessments. The specific justification for participants excluded under this criterion will be noted in study documents.\n* Participant or his\u002Fher immediate family is a member of the investigational team\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study\n* Heterosexual women of childbearing potential who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 12 weeks after the last dose. Highly effective contraceptive measures include:\n\n  * Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening\n  * Intrauterine device; intrauterine hormone-releasing system\n  * Bilateral tubal ligation\n  * Vasectomized partner\n  * And\u002For sexual abstinence.\n* Postmenopausal women must have amenorrhea for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.\n* Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. ‡Periodic abstinence (calendar, symptom-thermal, post-ovulation methods), withdrawal (coitus interrupts), spermicides only, and lactation amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.\n* Known systemic hypersensitivity to Dupilumab or the excipients of the drug product. This includes hypersensitivity reactions such as anaphylaxis, serum sickness, angioedema, urticaria, rash, erythema nodosum, and erythema multiforme.\n* If participant have or develop significant dysphagia, dilation of the esophagus using endoscopic, Savary or other kind of dilators will be allowed during the treatment with Dupilumab.","22 Years",{"count":158,"type":20},[250],"PHASE4","The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function.\n\nMain question this study aims to answer is: Whether Dupilumab helps improve muscle activity of the esophagus in participants with EOE?\n\nParticipants will:\n\nTake Dupilumab every week for 12 weeks. Visit the clinic before and after starting the medication. Keep a diary of symptoms.",[24],[206,254,109,255,256,257,258,259,260,261,262,263],"Dupixent","Eosinophilic esophagitis","Esophagitis","inflammation","Esophagus","Dysphagia","Difficulty swallowing","food stuck in throat","Motility","Gastroenterology","2024-12-06",{"date":266,"type":32},"2024-12-11",{"date":268,"type":32},"2024-11-10",{"date":270,"type":20},"2026-11-14",{"name":272,"class":39},"University of California, San Diego"]